News

Additionally, one-year survival rates were 74% for the ASA404 arm and 92% for the control arm. Since the majority of patients in both arms were alive after one

The Ventana board is now urging stockeholders not to tender any of their shares to Roche. The cancer diagnostics firm says it will “vigorously resist” Roche’s attempt to

Additionally, the drug reduced severe side effects like heart damage compared to a standard doxorubicin-based treatment. “We are excited by these results demonstrating that pixantrone is living up

The multi-center trial is expected to begin enrolling patients once the protocol regulatory review is completed. The trial has a two-stage design. Up to 21 NSCLC patients will

The primary objectives of the collaboration will be to develop models of resistance to Panzem (2ME2) in order to identify key proteins that may be potential novel drug

The agreement covers the Republic of Armenia, Georgia, and the Republic of Kazakhstan. ADA and CATH will bear any and all costs associated with the procurement of governmental

AMD currently affects approximately 10 million people in the US and is the leading cause of blindness in persons over age 65, according to an article published in

Results from the trial, which involved 407 postherpetic neuralgia (PHN) patients, did not demonstrate statistically significant efficacy relative to placebo in patients receiving an 1800mg total daily dose

The decision, which is subject to a possible appeal, prevents Ranbaxy from launching its drug before the basic Lipitor patent expires in November 2011. “Today’s decision is yet